APL-106 (uproleselan)

APL-106: (uproleselan): E-Selectin

APL-106, or Uproleselan (yoo’ pro le’ sel an), is an investigational, first-in-class, targeted inhibitor of E-selectin. Uproleselan is designed to block E-selectin (an adhesion molecule on cells in the bone marrow) from binding with blood cancer cells as a targeted approach to disrupting well-established mechanisms of leukemic cell resistance within the bone marrow microenvironment.

Uproleselan is currently in a comprehensive Phase 3 development program in AML and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the treatment of adult AML patients with relapsed or refractory disease.

In a Phase 1/2 clinical trial, uproleselan was evaluated in both newly diagnosed elderly and relapsed or refractory patients with AML. In both populations, patients treated with uproleselan together with standard chemotherapy achieved better-than-expected remission rates and overall survival compared to historical controls, which have been derived from results from third-party clinical trials evaluating standard chemotherapy, as well as lower-than-expected induction-related mortality rates. Treatment in these patient populations was generally well tolerated, with fewer than expected adverse effects.

GMI-1687

GMI-1687 is a rationally designed, innovative antagonist of E-selectin that is potentially suitable for subcutaneous (SC) administration. When given by SC injection in preclinical models, GMI-1687 has been observed to have equivalent activity to uproleselan, but at an approximately 250-fold lower dose. GlycoMimetics believes that GMI-1687 could be developed as a potential life-cycle expansion to broaden the clinical usefulness of an E-selectin antagonist to conditions where outpatient treatment is preferred or required. GMI-1687 is currently undergoing investigational new drug (IND)-enabling studies.

Uproleselan and GMI-1687 were discovered and developed by GlycoMimetics, Inc. Apollomics has development and commercialization rights for both agents in Greater China.

Trial Details
Type: Single Agent + Chemotherapy
Indication: Relapsed/Refractory Acute Myeloid Leukemia
Trial: NCT03616470
Trial Details
Type: Single Agent + Chemotherapy
Indication: Acute Myeloid Leukemia with induction chemotherapy
Trial: NCT03701308

Posters & Publications

Posters and Publications on our assets can be found here.